Acute Interstitial Nephritis (AIN): Student Handout
Updated March 2026 to reflect KDIGO 2026 guideline
Learning Objectives
By the end of this handout, you should be able to: - Recognize AIN as a major cause of AKI (accounting for 15-27% of cases) - Identify drug and non-drug causes of AIN - Understand the pathophysiology of drug-induced immune-mediated AIN - Recognize diagnostic limitations and pitfalls - Interpret urinalysis and novel biomarkers - Distinguish AIN from acute tubular necrosis - Recognize TINU syndrome (tubulointerstitial nephritis + uveitis) - Implement appropriate diagnostic and therapeutic approaches
Definition and Epidemiology
Acute Interstitial Nephritis: Immune-mediated inflammatory response affecting the kidney tubulointerstitium (interstitial space and tubules), sparing glomeruli (in primary AIN).
Incidence: - Accounts for 15-27% of kidney biopsies performed for unexplained AKI - Represents 1-3% of all AKI in general population - 70-75% are drug-induced (medication-related)
Mortality & Morbidity: - In-hospital mortality: ~20% of severe cases requiring dialysis - Many patients progress to chronic kidney disease if untreated - Early recognition and intervention critical for outcomes
Pathophysiology: The Immune Mechanism
The Pathogenic Process
Step 1: Initial Injury - Medication acts as hapten (chemical conjugates with protein) - Creates neo-antigen complex recognized as “foreign”
Step 2: Sensitization - Antigen-presenting cells process the hapten-protein complex - Helper T cells become activated - T cell–mediated hypersensitivity reaction develops
Step 3: Inflammatory Infiltrate - Lymphocytes (predominantly T cells) infiltrate interstitium - Eosinophils may be present (but inconsistently) - Inflammatory cytokines cause cellular injury
Step 4: Tubulointerstitial Damage - Tubule epithelial cells injured first - Interstitial edema and inflammation develop - Progressive fibrosis if untreated
Key Feature: Primary damage is immune-mediated, not dose-dependent. This explains why AIN can occur at therapeutic doses and after brief exposure.
Causes: Drug and Non-Drug Etiologies
Drug-Induced AIN (Most Common Cause)
Most Common Drug Causes (In Descending Frequency):
| Drug Class | Examples | Frequency |
|---|---|---|
| Antibiotics | Amoxicillin, ciprofloxacin, TMP-SMX, cephalosporins | 49% of drug-induced AIN |
| Proton pump inhibitors | Omeprazole, pantoprazole, lansoprazole | 14% of drug-induced AIN |
| NSAIDs | Ibuprofen, naproxen, indomethacin | 11% of drug-induced AIN |
| Diuretics | Thiazides, furosemide | ~5% |
| Anticonvulsants | Phenytoin, carbamazepine, allopurinol | Rare |
| Biologics | TNF-alpha inhibitors, monoclonal antibodies | Emerging cause |
Timing Patterns: - Antibiotics: Early onset (typically first 1-2 weeks) - NSAIDs: Intermediate timing (weeks 2-4) - PPIs: Delayed onset (weeks 3-8 or even months of exposure)
Clinical Presentation: The Classic Triad Is Uncommon
Classic Triad (Absent in ~2/3 of Cases)
- Fever (~20-30% of patients)
- Rash (~25% of patients)
- Eosinophilia (~20% of patients)
Critical Point: The absence of the classic triad does NOT exclude AIN. Many patients have AIN without any of these findings.
More Common Presentation
Most Typical Scenario: - Nonoliguric AKI (preserved or only mildly reduced urine output despite rising creatinine) - AKI developing days to weeks after new medication initiation - Bland or nonspecific symptoms (fatigue, anorexia, nausea) - Physical exam unremarkable (no fever, no rash visible)
Clinical Pearl: The key clue is nonoliguric AKI temporally related to new medication—this should raise high suspicion for AIN.
Diagnostic Approach: Urinalysis Findings
Urinalysis Pattern in AIN
| Finding | Typical Pattern | Significance |
|---|---|---|
| Proteinuria | Mild (usually <1-2 g/day) | Heavy proteinuria suggests glomerular disease |
| Hematuria | Mild to moderate | RBCs and WBCs present |
| Leukocyte esterase | 2+ (positive) | Indicates WBCs in urine |
| WBC count | Elevated (>5/hpf, often 13-138/µL) | Strong finding in AIN |
| WBC casts | May be present | Support diagnosis but not required |
| RBC casts | Absent (or rare) | Suggests GN instead; if present, consider dual pathology |
Urine Microscopy Interpretation
Characteristic Pattern: - Numerous WBCs without bacteria (sterile pyuria) - Occasional RBCs - White cell casts when present - Mild proteinuria - ABSENCE of RBC casts (helps differentiate from glomerulonephritis)
Important Distinction: - RBC casts = GN/RPGN (glomerular disease) - WBC casts = AIN (interstitial disease) - Muddy brown casts = ATN (tubular disease)
Tests That DON’T Help (Important Limitations)
Urine Eosinophils — do not order. [EVIDENCE-BASED — PMID 24052222]
Muriithi et al. (CJASN 2013) tested this properly: 566 patients who had both a urine eosinophil test and a native kidney biopsy within a week of each other, 91 with AIN. At a 1% Hansel-stain cutoff:
| Measure | Value | What it means |
|---|---|---|
| Sensitivity | 30.8% | Misses roughly 70% of biopsy-proven AIN |
| Specificity | 68.2% | Nearly a third of non-AIN patients test positive |
| PPV | 15.6% | Most positive results are wrong |
| NPV | 83.7% | Only moderately reassuring |
| LR+ | 0.97 | Changes nothing |
| LR− | 1.01 | Changes nothing |
- The likelihood ratios are the whole argument. Both sit at 1.0. A test that cannot move post-test probability in either direction is not a diagnostic test — it is a coin flip you paid for.
- Critical teaching point: the test fails in BOTH directions. A negative does not rule out AIN, and a positive does not rule it in. Older teaching emphasized only the rule-out failure; that framing understates the problem.
- Raising the cutoff to 5% drops sensitivity to 19.8% while specificity rises to 91.2% — still not clinically useful.
- Why older sources disagree: the four largest earlier series reported sensitivity 40–91% and specificity 52–95%, but none used kidney biopsy as the gold standard. Those numbers are an artifact of unvalidated reference standards.
Peripheral Eosinophilia: - Occurs in only minority of drug-induced AIN cases - Absence doesn’t exclude diagnosis - No diagnostic value as screening test
Novel Diagnostic Biomarkers
Beta-2 Microglobulin (B2M)
What It Is: Low-molecular-weight protein freely filtered and reabsorbed by proximal tubule. Elevation indicates tubular dysfunction.
Why It’s Mentioned: Historically discussed as AIN marker, but limited utility for general AIN diagnosis.
Current Role: - Moderate utility for TINU syndrome (tubulointerstitial nephritis + uveitis) - Limited for differentiation of AIN from ATN (both cause elevated B2M) - Pre-analytical instability (degrades at pH <6.0) limits reliability
Bottom Line: B2M is outdated for general AIN diagnosis; newer biomarkers superior.
CXCL9: The Emerging Gold Standard
What It Is: C-X-C motif chemokine ligand 9—a T cell–recruiting chemokine directly involved in immune response.
Why It’s Revolutionary: - Directly mechanistically linked to T cell–mediated inflammation (the actual AIN pathophysiology) - Not elevated in ATN (unlike B2M, NGAL) - Excellent stability (remains stable >24 hours at room temperature) - Fewer pre-analytical issues
Diagnostic Performance: | Metric | Value | |——–|——-| | AUC for AIN vs ATN | 0.84-0.95 (excellent) | | Sensitivity | 85-92% | | Specificity | 80-92% | | Outperforms all traditional biomarkers | YES |
Cutoff Interpretation: - High CXCL9 supports AIN diagnosis - Can distinguish AIN from other AKI causes - Increasingly available in specialized centers
Clinical Pearl: CXCL9 is the future of non-invasive AIN diagnosis; traditional markers (urinary eosinophils) are outdated.
Urinary Inflammatory Cytokines (KDIGO 2026, PP 2.5.3)
Emerging role: Urinary inflammatory cytokines (including but not limited to CXCL9) may be more useful than traditional markers for distinguishing AIN from other causes of AKI. The KDIGO 2026 guideline highlights this as a promising diagnostic approach, though availability remains limited outside research settings.
Drug Classification Framework and AIN Detection
KDIGO 2026 context: The guideline introduces a classification framework for drug effects on the kidney based on functional and damage biomarkers: - Function(+)/Damage(+): Drug causes both GFR decline and tubular damage (e.g., AIN with concurrent ATN features) - Function(-)/Damage(+): Drug causes tubular damage without immediate GFR change (subclinical AIN)
AIN-causing drugs fall into these damage-positive categories. Clinical implication: Biomarkers of tubular damage (NGAL, KIM-1, [TIMP-2]x[IGFBP-7]) may help identify drug-induced AIN earlier than creatinine alone, particularly in the Function(-)/Damage(+) window before GFR decline is apparent.
Kidney Biopsy: Definitive Diagnosis
Indication: When clinical diagnosis uncertain and diagnosis would change management.
Histologic Findings: - Dense lymphoplasmacytic infiltration of interstitium - Sparing of glomeruli (primary AIN) - Eosinophils may or may not be present - Tubular epithelial cell injury - Possible interstitial edema
Timing: Biopsy within 2-3 weeks of symptom onset optimal for diagnosis and prognosis assessment.
Not Always Necessary: In obvious cases (classic timeline + medication history + urinalysis pattern + clinical context), biopsy may be deferred if patient improving with drug discontinuation.
TINU Syndrome: A Special Entity
Definition and Epidemiology
TINU = Tubulointerstitial Nephritis + Uveitis Syndrome
Key Statistics: - Represents ~1-2% of uveitis cases in specialized centers - NOT just a pediatric disease: Affects patients aged 9-76 years - Female predominance (3:1 ratio) - Often misdiagnosed as isolated uveitis or drug-induced AIN alone
Important Note: Historical literature emphasized adolescent presentation; modern recognition shows substantial adult involvement (30-40% of cases are adults).
Clinical Presentation
Dual System Involvement: 1. Renal: Acute interstitial nephritis (elevated creatinine, pyuria, RBC+WBC casts possible) 2. Ocular: Bilateral anterior uveitis (eye pain, photophobia, visual symptoms) 3. Systemic: Often nonspecific (fever, malaise, arthralgia)
Timeline: - Simultaneous presentation common - Ocular findings may precede renal manifestations (diagnosed as isolated uveitis first) - Renal manifestations may occur months after ocular symptoms
Diagnostic Criteria
Definite TINU: 1. Kidney biopsy confirming AIN 2. Bilateral anterior uveitis on ophthalmology exam 3. No other systemic disease explaining both
Probable TINU: 1. Clinical AIN (elevated Cr + compatible urinalysis; biopsy not required if clinical picture clear) 2. Bilateral anterior uveitis confirmed 3. No alternative diagnosis
Role of B2M in TINU
This is where B2M has established utility: In TINU syndrome specifically, urinary B2M has superior sensitivity/specificity compared to general AIN.
Performance in TINU: - Sensitivity: 88-100% - Specificity: 70-80% - Elevated B2M + bilateral uveitis = high probability TINU
Practical Application: - Screen for bilateral anterior uveitis in any patient with AKI (ophthalmology exam) - If uveitis present + elevated B2M, TINU diagnosis highly likely - Refer to rheumatology/immunology for systemic workup
Management Principles
Immediate Steps
1. Discontinue Offending Medication - Most critical intervention - Discontinue as soon as AIN suspected - Many cases improve significantly with drug withdrawal alone
2. Supportive Care - Fluid and electrolyte management - Renal function monitoring - RRT if necessary (same indications as ATN)
Corticosteroid Therapy
Evidence & Recommendation: - Corticosteroids may improve outcomes if started early (within 2-3 weeks) - Typical regimen: Prednisone 0.5-1 mg/kg/day (or IV methylprednisolone in severe cases) - Duration: Usually 2-4 weeks with taper
Outcome Data: - 49% complete recovery (creatinine returns to baseline) - 39% partial recovery (improved but not to baseline) - 12% no recovery (permanent renal impairment)
Factors Associated with Better Outcomes: - Earlier steroid initiation (within 1-2 weeks) - Shorter duration of drug exposure before diagnosis - Lower peak creatinine at presentation
Clinical Pearl: If biopsied early and treated with steroids early, outcomes improve; delayed diagnosis/treatment associated with permanent renal damage.
When to Escalate to Immunosuppression
Some cases with severe AIN or inadequate response to steroids may require: - Mycophenolate mofetil (MMF) - Tacrolimus - Other immunosuppressive agents - Typically reserved for severe/refractory cases
Differential Diagnosis: AIN vs. ATN vs. RPGN
| Feature | AIN | ATN | RPGN |
|---|---|---|---|
| Mechanism | Immune-mediated inflammation | Tubular necrosis | Glomerular crescents |
| Urine output | Nonoliguric (preserved) | Oliguric or nonoliguric | Often oliguric |
| Proteinuria | Mild (<1-2 g/day) | Mild | Heavy (often >3 g/day) |
| RBC casts | Absent | Absent | PRESENT (diagnostic) |
| WBC casts | May be present | Absent | May be present |
| Muddy brown casts | Absent | PRESENT | Absent |
| WBC in urine | Elevated (13-138/µL) | Low | Low |
| Timeline | Days-weeks post-medication | Hours-days post-injury | Days-weeks |
| Classic triad | Rare | N/A | Hemoptysis possible |
Practice Questions
Question 1: A 54-year-old on omeprazole (3 months) for GERD develops AKI (Cr 1.1 to 2.8 in 1 week). Urinalysis: WBC 45/hpf, RBCs 8/hpf, protein 1+, no casts. Most likely diagnosis? A) Acute tubular necrosis B) Acute interstitial nephritis C) Rapidly progressive glomerulonephritis D) Prerenal AKI
Answer: B) Acute interstitial nephritis. The timeline (3-month PPI use with recent AKI), nonoliguric pattern (Cr rise despite presumably preserved urine output), elevated WBCs in urine without casts, and mild proteinuria are classic for drug-induced AIN. PPIs are 2nd-most common drug cause of AIN. Absence of RBC casts excludes RPGN. The absence of muddy brown casts argues against ATN.
Question 2: A 32-year-old woman presents with red eyes (bilateral anterior uveitis, confirmed by ophthalmology) and AKI (Cr 2.1). Urinalysis: WBCs, mild proteinuria, no RBC casts. Urine B2M elevated. Most likely diagnosis? A) Goodpasture syndrome B) Systemic lupus erythematosus C) TINU syndrome D) Medication-induced AIN only
Answer: C) TINU syndrome. The combination of bilateral anterior uveitis (ocular finding) + AIN (renal finding) + elevated B2M = TINU syndrome diagnosis. This is the specific scenario where B2M has excellent diagnostic utility. Goodpasture would present with hemoptysis and RBC casts. SLE possible but bilateral uveitis less typical.
Question 3: A 68-year-old on amoxicillin (day 7) develops AKI. Biopsy confirms AIN. Current Cr is 3.2 (baseline 1.0). Which statement represents best management? A) Discontinue amoxicillin and observe; most cases self-limited B) Discontinue amoxicillin + start prednisone immediately (within first 2-3 weeks) C) Discontinue amoxicillin + start dialysis; steroids contraindicated in infections D) Continue amoxicillin (needed for infection); add corticosteroids for kidney protection
Answer: B) Discontinue amoxicillin + start prednisone immediately (within first 2-3 weeks). Antibiotic-induced AIN requires both: (1) drug discontinuation AND (2) corticosteroids if started early. Early steroid therapy (within 1-3 weeks) improves outcomes (49% complete recovery vs lower rates if delayed). Continuing the offending drug defeats the purpose. Dialysis may be needed for complications, but shouldn’t delay appropriate therapy.
Key Takeaways
- AIN accounts for 15-27% of biopsy-proven AKI — must maintain high suspicion
- Classic triad absent in 2/3 of cases — don’t rely on fever/rash/eosinophilia
- Nonoliguric AKI + new medication = suspect AIN until proven otherwise
- Urine eosinophils unreliable (outdated test; don’t order)
- CXCL9 emerging biomarker for non-invasive AIN diagnosis
- Discontinue offending agent immediately — most critical intervention
- Early corticosteroids improve outcomes if started within 2-3 weeks
- TINU is not just pediatric — affects adults; requires ophthalmology screening
See Also
Clinical Content (01-Clinical-Medicine/Nephrology)
- AKI Hub - Full Clinical Reference
- Essential Renal Laboratory Tests
Butler-COM Resources
- Butler COM - Nephrology Deep Dive
Also on this topic
The same subject at other levels of depth.
- Lecture: 💧 Acute Interstitial Nephritis (AIN)
- Interactive case: Acute Interstitial Nephritis